Navigation Links
ImQuest BioSciences and Arisyn Therapeutics Announce Strategic Partnership to Develop Infectious Disease and Cancer Drugs
Date:4/29/2009

FREDERICK, Md., April 29 /PRNewswire/ -- ImQuest BioSciences and Arisyn Therapeutics jointly announced today that they have entered into a strategic drug development partnership to provide support necessary to develop Arisyn's portfolio of novel inhibitors for the treatment of infectious disease and cancer. Arisyn has recently announced its acquisition of a series of inhibitors with demonstrated preclinical efficacy against HIV, HCV, HTLV-I, influenza virus, herpes viruses and cancer. These inhibitors were originally discovered and developed by The Proctor & Gamble Company. Lead molecules from the portfolio have already been evaluated in Phase 1 human clinical trials for the treatment of HIV and cancer, and an IND-application has been prepared for submission to the FDA to initiate trials for HCV therapy.

"The Arisyn compounds represent an entirely new treatment paradigm by effectively suppressing the ability of the HIV or HCV-infected cells to act as the factories of progeny virus production," stated Robert W. Buckheit, Jr., Ph.D., Director of Research and Development for Arisyn and President and Chief Scientific Officer of ImQuest BioSciences. "The compounds have proven efficacy and safety in preclinical studies and their successful development will be of immense benefit to the millions of individuals living with HIV and HCV infection."

ImQuest BioSciences, a Contract Research service provider specializing in the discovery and development of anti-infective and anti-cancer agents, will provide all required support to initiate human clinical trials with lead products ATI-0312 for HIV and ATI-0810 for HCV and will initiate mechanistic studies to define the unique virus transcription inhibitory mechanism of action of the class of inhibitors. ImQuest will also lead Arisyn's efforts to develop next generation inhibitors from structure activity relationship studies and target-based drug design programs.

"This p
'/>"/>

SOURCE ImQuest Life Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program
2. ImQuest Presents Data on the Anti-Hepatitis B Virus Activity of Pyrimidinediones at the 13th ISVHLD Meeting in Washington D.C.
3. ImQuest Presentations at CROI Report Significant Advances in Therapeutic and Microbicide Product Development Programs
4. ImQuest Presents IND-Enabling Safety Pharmacology and Pharmacokinetic Data for the Therapeutic HIV Compound IQP-0410 at Conference on Retroviruses and Opportunistic Infections
5. ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission
6. ImQuest Awarded SBIR Grant to Define the Mechanism of Action of Their Lead Anti-HIV Therapeutic Compound IQP-0410
7. LaVoie Group Selected by Vaccine Developer, Profectus BioSciences, as Agency of Record
8. Former GE Healthcare Director, Per Foss Appointed CEO for HUNT Biosciences
9. Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast
10. Cell Biosciences Launches Next-Generation Protein Characterization System
11. Cell Biosciences Announces Publication in Nature Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the ... steps for its Oral Amphotericin B program.  The ... in vitro work involving samples from HIV/AIDS ... to complete pre clinical studies and regulatory filings ... clinical trial, utilizing approximately $700,000 of funding and ...
(Date:10/22/2014)... DIEGO and HONG KONG ... innovative rare disease therapeutics enterprise, announced today that rare ... the company as vice president, research. Dr. McKew brings ... including key leadership positions at the National Institutes of ... its acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts ...
(Date:10/20/2014)... Convey Computer , the leader in hybrid-core ... University won first place in the 2014 MemoCODE ... team’s solution achieved the highest overall performance in the ... finisher. , Experts from all segments of the commercial ... using a variety of design tools, hardware and software. ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... REHOVOT, Israel and JERSEY CITY, New Jersey, July 3, ... of microRNA-based diagnostics and therapeutics, announced today,it will present ... at 8:30 am EST at the Mandarin Oriental Hotel ... (Nasdaq: ROSG ) is a leader in the ...
... company to offer choice of two distinct drugs on ... separate drug-eluting stent platforms, ... ) today announced that the U.S. Food and Drug,Administration (FDA) ... of coronary artery disease. The,PROMUS Stent is a private-labeled XIENCE(TM) ...
... Bioniche,s growing line of injectable ... ... and manufacturer of injectable pharmaceuticals, announced today,the acquisition of Baxter Healthcare Corporation,s ... mg/mL, 15 mL vial -- ENLON-PLUS(R) (edrophonium chloride, USP and atropine ...
Cached Biology Technology:Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System 2Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System 3Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System 4Bioniche Pharma Acquires Baxter's ENLON(R) and ENLON-PLUS(R) 2
(Date:10/17/2014)... critical and pertinent for practicing physicians and clinicians given ... The Journal, Disaster Medicine and Public Health Preparedness ... Public Health, to surround the public, medical professionals and ... , On October 17, the journal published ... was prepared by Dr. Eric Toner, internist and emergency ...
(Date:10/16/2014)... Mary,s Virginia Institute of Marine Science have received ... Agency to identify the streams and wetlands most ... to help local governments and citizens conserve these ... a dataset of tidal-marsh observations first gathered by ... historical baseline can today,s researchers accurately map the ...
(Date:10/16/2014)... women experienced improvements in vaginal atrophy, with no ... after 12 weeks of daily 10 milligram (mg) ... supplement previously shown to help relieve certain menopause ... reported in a poster at the North American ... "These data documented improved vaginal epithelium, without significant ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... us, deep within Earth,s crust, life is astir. Organisms ... thinking of life. Instead, thriving there are microbes, the ... the biological diversity of these deep biosphere microorganisms may ... about them is still unknown, including the origin of ...
... at the Hebrew University of Jerusalem has found a way to ... those that don,t have one. Smell plays an important role ... fruit and vegetables, perfume, and even a partner. And yet, smell ... what we taste, explains Prof. Alexander Vainstein, who is heading the ...
... SPRING HARBOR, N.Y. (Oct. 7, 2008) ... and analysis has just been released by Cold ... day-to-day use in the laboratory, it includes essential ... experimental strategies, and troubleshooting advice on the most ...
Cached Biology News:Deep biosphere research points to new methods for recovering petroleum 2Deep biosphere research points to new methods for recovering petroleum 3Deep biosphere research points to new methods for recovering petroleum 4Deep biosphere research points to new methods for recovering petroleum 5Scent on demand: Hebrew University scientists enhance the scent of flowers 2New lab manual focuses on essential methods for purifying and characterizing proteins 2
APO-BrdU™ TUNEL Assay Kit *with Alexa Fluor® 488 anti-BrdU* *60 assays*...
...
IMAGEQUANT 300 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
RayBio Human Cytokine Antibody Array 1.1 (4 array membranes) with Accessory, detects 20 cytokines (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: